AGA technical review on irritable bowel syndrome.

By D. Drossman, Michael Camilleri, Emeran A. Mayer, W. Whitehead. Gastroenterology, 2002

1,460 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Brain–Gut–Microbe Communication in Health and Disease (2011, background): “It is characterized by the presence of abdominal pain or discomfort, an alteration in bowel habit, and the absence of reliable biomarkers (Thompson et al., 1999; Drossman et al., 2002; Clarke et al., 2009b).”
Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. (2003, methodology): “Participants received either (3) DES, a tricyclic antidepressant administered as 1 pill (50 mg) per day for 1 week, 2 pills (100 mg) per day for 1 week, and then 3 pills (150 mg) per day from week 3 to week 12, or (4) PLA administered in the same fashion.”
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome (2010, background): “[7,8] It is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits.”
Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR (2005, background): “Psychosomatic factors, altered GI motility, and visceral hypersensitivity have been proposed as possible reasons behind IBS (1).”
Anxiety disorders and comorbid medical illness. (2008, background): “[31] Drossman DA, Camilleri M, Mayer EA, Whitehead WE.”